サインイン 無料でサインアップします。

Kazia TherapeuticsのQuick ratio

Kazia TherapeuticsのQuick ratioは何ですか。

Kazia Therapeutics LimitedのQuick ratioは1.58です。

Quick ratioの定義は何ですか。



当座比率は、短期債務を即座に満たすために迅速な資産を使用する企業の能力を測定する流動性比率です。

The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.

ASXのセクタHealth CareにおけるQuick ratioの企業と比べるKazia Therapeutics

Kazia Therapeuticsは何をしますか。

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Kazia Therapeuticsと類似のquick ratio